Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in four phase 3 odyssey trials with/without statin background. (September 2016)

Record Type:
Journal Article
Title:
Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in four phase 3 odyssey trials with/without statin background. (September 2016)
Main Title:
Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in four phase 3 odyssey trials with/without statin background
Authors:
Robinson, J.G.
Farnier, M.
Kastelein, J.J.
Roth, E.M.
Taskinen, M.R.
Colhoun, H.M.
Brunet, A.
DiCioccio, A.T.
Lecorps, G.
Pordy, R.
Baccara-Dinet, M.T.
Cannon, C.P.
Abstract:
Is Part Of:
Atherosclerosis. Volume 252(2016)
Journal:
Atherosclerosis
Issue:
Volume 252(2016)
Issue Display:
Volume 252, Issue 2016 (2016)
Year:
2016
Volume:
252
Issue:
2016
Issue Sort Value:
2016-0252-2016-0000
Page Start:
e231
Page End:
Publication Date:
2016-09
Subjects:
Arteriosclerosis -- Periodicals
Electronic journals
616.136
Journal URLs:
http://www.sciencedirect.com/science/journal/00219150 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/00219150 ↗
http://www.elsevier.com/journals ↗
DOI:
10.1016/j.atherosclerosis.2016.07.219 ↗
Languages:
English
ISSNs:
0021-9150
Deposit Type:
Legaldeposit
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:
British Library DSC - 1765.874000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:
21866.xml